Eaglenos Sciences, Inc.

Eaglenos Sciences, Inc. is a POCT company with a mission to enhance health through precise, quick, and convenient diagnosis and health management. Established in 2017 and headquartered in China, Eaglenos brings together top talents from various fields including chemistry, materials science, electronics, software, machinery, and biomedical engineering, with a focus on quality, innovation, cooperation, and accountability.

Since its official launch in June 2018, Eaglenos has introduced a range of precise POCT products targeting diseases such as diabetes, hyperuricemia, and cardiovascular and cerebrovascular conditions. The company has received a significant Series A investment of CNY150.00M on 29 May 2023, led by 3E Bioventures Capital, InnoMed Capital, Huatai Zijin Investment, and Grand Yangtze Capital.

Eaglenos' innovation is evident in its development of three key product platforms: cartridge testing, strip testing, and continuous monitoring. The company's R&D base in Jiangbei New Area covers 9,000 square meters and is equipped with international standard R&D labs, GMP production workshops, and automated production lines.

Among its product offerings are blood gas analyzers and single-use cartridges, electrolyte analyzers and single-use cartridges, as well as meters and strips for various health metrics including blood glucose, uric acid, ketone, lactate, total cholesterol, hemoglobin, and creatinine (eGFR). Eaglenos is committed to expanding its precision testing product line and delivering high-quality health management products and services globally to protect human health.